The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
An RNS is based on news not the time elapsed since the last one
When they have something to tell us we will get the RNS we all want.
Until then patience and a reality check on how long it takes to develop a drug trial, particularly one that’s so important to the company’s existence.
Come on Sir Stephen Holgate .
Come on Sir Stephen Holgate .
Do you know it's been 6 months since our last RNS, we must be due an annojncement.
Come on Dr .
The reality is trials and the science that backs them up takes a great deal of time to bring to fruition.
People got a false sense of urgency during COVID that things would happen within months. You could equally say that one of our biggest failures in Sprinter was rushing the trial design.
I remain patient knowing we will either get an update before H2 is ends or at the AGM. Our largest investor appears equally calm about the finances and our progress.
Well done to the sleuths. Either our stock has degraded prematurely or they decided to fork out more valuable cash for…what!
They renew every year I think so nothing new here and definitely not a 'nugget' of positive news.
May next week with no update to shareholders in 2024.
Mani - didnt you tell me years ago - no shelf life??
Nice - its made in Argentina.......keep it cheap
Unlike us TFG will know exactly where we are in the process to starting
our P2's and what the finances are. I would not be surprised if they are now
looking at an intervention as they have given SNG over 2 years to get
back on track... Of course that will not be shared by SNG to mere PI's
but if accurate it may be a good thing.. As I have previously said RM
has a conflict of interest...Let things drag on and keep getting £350K a
year from existing funds or risk the lot on P2's and put his job in jeopardy
if the results are not conclusive...! Many of us have lost respect for RM
as our CEO, have TGF run out of patience...?? It is possible more staff
have gone and as they were not Directors it was not reported!
Before Fruits and Tommy intervene, yes we are still in H1 so we
could still be on track, but the lack of any social media posts/tweets
and results later than last year does not give a positive impression IMHO!
My gut is that SNG will say they are waiting for final UNIVERSAL results
and make any delay look like being prudent rather than incompetent!
TGF are not going to let the company their investment drop down to zero, so am sure they are making their voice heard.
He is on our website as part of the Senior Managment Team..
I think it is reasonable we should be told he is departing... Maybe
he was pushed and SNG would rather not say anything.....
It seems there is a clearout at SNG..... ! Are TGF taking a more
active role ??? Maybe TGF have been asked to support
the P2's or a JV is being discussed and the surplus staff
have to go......I'd say something is going on... RM has
been adding to the team since SPRINTER so If there
is an obvious cull I doubt he is the instigator!! IMHO!
GLA!
It should at the very least get a mention in the update with results..
There was no RNS for his arrival so there will be no RNS for his departure. Same for Hennings & Clarke.
Francis has always been part time consultant.
All he said is he’s open for more consulting work which given where we are with synairgen is no great surprise
Goodness me, where is the communication from Synairgen to inform us of key people leaving the business? They were happy to announce their arrivals.
As before, I like and believe in SNG001. But deary deary, I do not believe the management team are capable. Unless they pull a rabbit out of the hat at or before the AGM, I cannot support them going forward.
“How do people find these nuggets, impressive?”
IMHO, It is simply because they correspond to the outline strategy that was communicated last September. There is nothing definite about them until we receive an update affirming that the strategy is on track. If the company has managed to achieve their planned tasks without a hitch, we should be updated before the end of June.
GLALTIs.
Do we need to manufacture more for our trials or is
this housekeeping....Our stocks must be nearly 5 years old..!
Looks like the new CFO is slimlining SNG... HOORAY!
It is a shame this was not done years ago. It could also
be TGF playing their hand if indeed money is short for
planned trials and a raise has become inevitable..
The waste of the placing funds has been frustrating..
Paying staff who clearly had no role after SPRINTER
results was a huge mistake... Let's hope the new CFO
can get us through the P2's without the need for
a significant raise. As April draws to a close with no
results or updates, I will be surprised if we are told
we definitely have enough for the trials and get
a H1 start date.... But you never know!!
How do people find these nuggets, impressive
Posted from Casanova labhttps://link.springer.com/article/10.1007/s10875-024-01708-7
Good to see they are cutting costs.
Should have done it earlier and they should have informed us more but we all know this company doesnt care about its small investors.
As a result they have benefitted traders like me over LTH that stumped up the money. Sad but true...
Enough looking back. Lets make money together ;)
Did we renew the photocopier deal at the same time?
I guess the trolls are wrong and we are not closing down then.
Poor Mr Costs will have to find some other angle to cry about